Brand Introduction
Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk, and the world's first approved oral GLP-1 medication, used for the treatment of type 2 diabetes and long-term weight management.
Brand Background and R&D History
Semaglutide was developed by Novo Nordisk, a Danish pharmaceutical company founded in 1923 and a global pioneer and leader in diabetes care. Its development story began in 2002, when Danish researcher Thomas Kruse and his team were given a highly challenging task: to modify the natural GLP-1 hormone so that its effect could last from only a few minutes to a full week.
The R&D process was far from smooth. The team synthesized hundreds of variants and tested them one by one — semaglutide was actually compound number 217; the first 216 versions were eliminated due to insufficient stability or potency. The final breakthrough came from a clever piece of chemical engineering: scientists attached a fatty acid side chain to the molecule, enabling it to bind to albumin in the blood and form a protective "shield," greatly extending the drug's circulation time in the body. This approach extended semaglutide's half-life to about one week, laying the foundation for once-weekly dosing and the later development of an oral formulation.
Product Portfolio
Semaglutide is currently available under multiple brand names and formulations:
| Brand Name | Formulation | Primary Indication | First Approval |
|---|---|---|---|
| Ozempic | Injection | Type 2 diabetes | 2017 (US) |
| Rybelsus | Oral tablet | Type 2 diabetes | 2019 (US) |
| Wegovy | Injection | Weight management | 2021 |
| Wegovy Oral Tablet | Oral tablet | Weight management | 2026 (UK) |
Among these, Rybelsus (semaglutide tablets) is the first and only approved oral GLP-1 receptor agonist tablet. Approved by the US FDA in 2019, it marked the transition of GLP-1 therapy from the injection era to the oral era.
Mechanism of Action
Semaglutide is a GLP-1 analogue with 94% sequence homology to natural human GLP-1. It mimics the action of the natural GLP-1 hormone by selectively binding to and activating the GLP-1 receptor.
Its core mechanisms of action include:
-
Glucose-dependent glucose lowering: stimulates insulin secretion and inhibits glucagon release when blood glucose is elevated; it does not act when blood glucose is low, thereby reducing the risk of hypoglycemia
-
Delayed gastric emptying: mildly delays early postprandial gastric emptying, slowing the rate at which glucose enters the bloodstream
-
Central appetite regulation: acts on brain regions that regulate appetite, increasing satiety and reducing hunger and food cravings, thereby lowering energy intake
Key Data
In the PIONEER clinical trial program for Rybelsus, a total of 9,543 adults with type 2 diabetes were enrolled. Results showed:
-
Rybelsus was superior to sitagliptin and empagliflozin in lowering blood glucose
-
Treatment reduced body weight by up to 4.4 kg
-
The most common adverse event was mild to moderate nausea, which diminished over time
The R&D contribution of semaglutide has been widely recognized by the scientific community. In 2024, scientists involved in the pioneering work on GLP-1 drugs were awarded the Lasker Award — often regarded as a precursor to the Nobel Prize.
Brand Positioning and Vision
Novo Nordisk positions semaglutide as a core product for addressing serious chronic diseases, with the vision of "driving change to defeat serious chronic diseases." Semaglutide has evolved from an initial diabetes treatment to weight management, and is being explored for broader applications in cardiovascular, kidney, and liver diseases. This evolution reflects Novo Nordisk's mission of "a century of innovation" — from producing insulin in Denmark in 1923 to launching the first oral GLP-1 in 2019, continuously driving paradigm shifts in the treatment of diabetes and metabolic diseases.